BPTH — Bio Path Holdings Share Price
0.000.00%
Last trade - 00:00- $3.23m
- $2.18m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.33 | ||
| Price to Tang. Book | 7.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1205.71% | ||
| Return on Equity | -220.02% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
Directors
- Peter Nielsen CHM (72)
- Douglas Morris DIR (65)
- Paul Aubert IND (51)
- Heath Cleaver IND (47)
- Martina Molsbergen IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 31st, 2014
- Public Since
- January 11th, 2006
- No. of Shareholders
- 187
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,565,306
- Address
- 4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE, 77401
- Web
- https://www.biopathholdings.com/
- Phone
- +1 8327421357
- Contact
- Douglas Morris
- Auditors
- Ernst & Young LLP
Upcoming Events for BPTH
Q2 2024 Bio Path Holdings Inc Earnings Release
Similar to BPTH
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Bio Path Holdings share price?
As of Today at 19:04 UTC, shares in Bio Path Holdings are trading at $4.29. This share price information is delayed by 15 minutes.
How has the Bio Path Holdings share price performed this year?
Shares in Bio Path Holdings last closed at $4.29 and the price had moved by -85.08% over the past 365 days. In terms of relative price strength the Bio Path Holdings share price has underperformed the S&P500 Index by -87.59% over the past year.
What are the analyst and broker recommendations for Bio Path Holdings?
The overall consensus recommendation for Bio Path Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Bio Path Holdings dividend yield?
Bio Path Holdings does not currently pay a dividend.
Does Bio Path Holdings pay a dividend?
Bio Path Holdings does not currently pay a dividend.
When does Bio Path Holdings next pay dividends?
Bio Path Holdings does not currently pay a dividend.
How do I buy Bio Path Holdings shares?
To buy shares in Bio Path Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bio Path Holdings?
As of the previous close price of $4.29, shares in Bio Path Holdings had a market capitalisation of $3.23m.
Where are Bio Path Holdings shares listed?
Here are the trading details for Bio Path Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BPTH
What kind of share is Bio Path Holdings?
Based on an overall assessment of its quality, value and momentum Bio Path Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bio Path Holdings share price forecast for 2024?
The analyst consensus target price for shares in Bio Path Holdings is $40.00. That is 832.4% above the last closing price of $4.29.
Analysts covering Bio Path Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$18.71 for the next financial year.
What is the trend in the Bio Path Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bio Path Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -73.52%.
As of the last closing price of $4.29, shares in Bio Path Holdings were trading -56.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bio Path Holdings PE Ratio?
The Bio Path Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bio Path Holdings?
Bio Path Holdings' management team is headed by:
- Peter Nielsen - CHM
- Douglas Morris - DIR
- Paul Aubert - IND
- Heath Cleaver - IND
- Martina Molsbergen - IND